Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. GDTC
stocks logo

GDTC

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Valuation Metrics

The current forward P/E ratio for CytoMed Therapeutics Ltd (GDTC.O) is -10.88, compared to its 5-year average forward P/E of -15.30. For a more detailed relative valuation and DCF analysis to assess CytoMed Therapeutics Ltd 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-15.30
Current PE
-10.88
Overvalued PE
-11.48
Undervalued PE
-19.12

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
56.87
Current PS
0.00
Overvalued PS
74.23
Undervalued PS
39.52
Intellectia AI SwingMax
Intellectia AI SwingMax

Financials

Annual
Quarterly

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Financial AI Agent
Financial AI Agent

GDTC News & Events

Events Timeline

(ET)
2025-11-18
09:33:16
CytoMed finalizes purchase of TC BioPharm's T cell technology
select
2025-11-06 (ET)
2025-11-06
08:36:51
Cytomed Therapeutics obtains funding for its subsidiary LongevityBank
select
2025-10-14 (ET)
2025-10-14
08:04:03
Cytomed Proposes Cash Offer for Possible Acquisition of TC BioPharm
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.0
10-02Newsfilter
CytoMed Therapeutics Reveals Collaborative Study with The University of Texas, MD Anderson Cancer Center, Highlighting the Promise of Allogeneic γδ T Cells for Acute Myeloid Leukemia

  • Research Publication: CytoMed Therapeutics has published a preclinical study in collaboration with MD Anderson Cancer Center, highlighting the potential of their allogeneic γδ T cell therapy for treating acute myeloid leukemia (AML).

  • Future Clinical Trials: The company plans to advance its γδ T cell-based products into clinical trials in Southeast Asia, aiming to provide novel immunotherapy options for patients with limited treatment alternatives.

[object Object]
Preview
8.5
08-28Newsfilter
CytoMed Therapeutics Expands into Autoimmune Diseases Following Recent Cord Blood Bank Acquisition

  • Company Overview: CytoMed Therapeutics, a Singapore-based biopharmaceutical company, focuses on developing affordable donor-derived cell-based immunotherapies for various cancers and has successfully expanded clinical-scale natural killer (NK) cells from long-preserved cord blood units.

  • New Business Structure: The company is reorganizing to create LongevityBank, which will focus on autologous therapies using personalized cellular banking services, while CytoMed will concentrate on allogeneic therapies that are already in clinical trials.

  • Cord Blood Bank Acquisition: CytoMed's acquisition of a licensed cord blood bank in Malaysia allows access to valuable cord blood resources, enhancing the development of new therapeutics for autoimmune diseases and cancers.

  • Future Growth Plans: The company aims to spin off LongevityBank as an independent entity, leveraging its cost-effective R&D infrastructure to produce both autologous and allogeneic cell therapies, with expectations of positive revenue contributions from the restarted banking business.

[object Object]
Preview
8.5
08-19Newsfilter
CytoMed Therapeutics Limited Unveils At-the-Market (ATM) Offering Initiative

  • Company Announcement: CytoMed Therapeutics Limited has entered into an At-the-Market Sales Agreement with R.F. Lafferty & Co., Inc. to sell ordinary shares valued up to $4,304,945.

  • Use of Proceeds: The funds raised will be used for general corporate purposes, including business diversification, development initiatives, and potential acquisitions or strategic investments.

  • Recent Developments: Since acquiring a cord blood bank in August 2024, CytoMed has gained approximately 2,500 new customer sign-ups, contributing to its revenue in 2025.

  • Forward-Looking Statements: The press release includes forward-looking statements about the company's plans and performance, which are subject to risks and uncertainties that may affect actual results.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is CytoMed Therapeutics Ltd (GDTC) stock price today?

The current price of GDTC is 1.85 USD — it has increased 5.71 % in the last trading day.

arrow icon

What is CytoMed Therapeutics Ltd (GDTC)'s business?

CytoMed Therapeutics Limited is a biopharmaceutical company. It is focused on harnessing its licensed proprietary technologies, namely gamma delta T cell and gamma delta Natural Killer T cel to create cell-based immunotherapies for the treatment of human cancers. The development of its technologies has been inspired by the clinical success of existing CAR-T in treating hematological malignancies as well as the clinical limitations and commercial challenges in extrapolating the CAR-T principle into treatment of solid tumors. Its product candidates include CTM-N2D, iPSC-gdNKT, and CTM-GDT. CTM-N2D is a lead product candidate that consists of expanded gamma delta T cells grafted with NKG2DL-targeting CAR to enhance anti-cancer cytotoxicity. The iPSC-gdNKT product candidate utilizes iPSC as a starting material to generate gdNKT, which is a synthetic hybrid of a gamma delta T cell and a NK cell. The Company also has the allogeneic gamma delta T cell technology, namely TCB-002.

arrow icon

What is the price predicton of GDTC Stock?

Wall Street analysts forecast GDTC stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for GDTC is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is CytoMed Therapeutics Ltd (GDTC)'s revenue for the last quarter?

CytoMed Therapeutics Ltd revenue for the last quarter amounts to NaN USD, decreased % YoY.

arrow icon

What is CytoMed Therapeutics Ltd (GDTC)'s earnings per share (EPS) for the last quarter?

CytoMed Therapeutics Ltd. EPS for the last quarter amounts to USD, decreased % YoY.

arrow icon

What changes have occurred in the market's expectations for CytoMed Therapeutics Ltd (GDTC)'s fundamentals?

The market is revising No Change the revenue expectations for CytoMed Therapeutics Limited (GDTC) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -4.15%.
arrow icon

How many employees does CytoMed Therapeutics Ltd (GDTC). have?

CytoMed Therapeutics Ltd (GDTC) has 28 emplpoyees as of December 05 2025.

arrow icon

What is CytoMed Therapeutics Ltd (GDTC) market cap?

Today GDTC has the market capitalization of 21.71M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free